A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin (SURPASS-5)
I8F-MC-GPGI - ClinicalTrials.gov - NCT04039503
The purpose of this study is to compare the safety and efficacy of the study drug tirzepatide to placebo in participants with type 2 diabetes that are already on insulin glargine, with or without metformin. Participants will administer tirzepatide or placebo along with their previous glucose lowering medications.
Trial Summary
Age Range
≥18 yearsConditions the trial is for
Type 2 DiabetesWhat the trial is testing?
TirzepatideCould I receive a Placebo?
YesEnrollment Goal
475Trial Dates
Aug 30, 2019 - Jan 13, 2021How long will I be in the trial?
Your participation could last about 47 weeks and may include up to 23 visits to the study center.Trial Phase
IIILilly Trial Alerts
Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.
You will complete the questionnaire on another website.YesNo